Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Efficacy and Safety Profile of Romiplostim in Patients with Persistent Thrombocytopenia Following Chemotherapy

  • By

  • Andrew B. Song

  • Gerald A. Soff

  • September 28, 2026

Share

  • 1

    Cytopenias from chemotherapy often lead to treatment delays and reduced relative dose intensity, impacting patient outcomes.

  • 2

    No FDA-approved agents exist for the treatment of chemotherapy-induced thrombocytopenia, creating an unmet medical need.

  • 3

    Romiplostim has shown significant efficacy in improving platelet counts in patients with persistent chemotherapy-induced thrombocytopenia.

  • 4

    Recent trials demonstrated that TPO receptor agonists can maintain chemotherapy dose intensity by correcting persistent thrombocytopenia.

  • 5

    Guidelines recommend considering off-label use of romiplostim for managing persistent chemotherapy-induced thrombocytopenia.

Original Source(s)

Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia

  • by Andrew B. Song, Gerald A. Soff

  • September 28, 2026

Related Content

Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology

Machine Learning Alone Won’t Take Vibrational Spectroscopy Into the Clinic

Standardized preprocessing, multicenter datasets, external validation, and interpretable models may matter more than further gains in classification accuracy

  • September 30, 2026

  • 3 min
Deep learning-based segmentation of peritoneal cancer index regions from CT imaging